CA2185129A1 - Methods to diagnose and treat hiv-1 infection - Google Patents

Methods to diagnose and treat hiv-1 infection

Info

Publication number
CA2185129A1
CA2185129A1 CA002185129A CA2185129A CA2185129A1 CA 2185129 A1 CA2185129 A1 CA 2185129A1 CA 002185129 A CA002185129 A CA 002185129A CA 2185129 A CA2185129 A CA 2185129A CA 2185129 A1 CA2185129 A1 CA 2185129A1
Authority
CA
Canada
Prior art keywords
seq
arg
hiv
gly
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002185129A
Other languages
English (en)
French (fr)
Inventor
Angeline Douvas
Glenn Ehresmann
Yoshi Takehana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2185129A1 publication Critical patent/CA2185129A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rehabilitation Therapy (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA002185129A 1994-03-14 1995-03-13 Methods to diagnose and treat hiv-1 infection Abandoned CA2185129A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21374394A 1994-03-14 1994-03-14
US08/213,743 1994-03-14

Publications (1)

Publication Number Publication Date
CA2185129A1 true CA2185129A1 (en) 1995-09-21

Family

ID=22796323

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002185129A Abandoned CA2185129A1 (en) 1994-03-14 1995-03-13 Methods to diagnose and treat hiv-1 infection

Country Status (6)

Country Link
EP (1) EP0750636A1 (no)
JP (1) JPH10504798A (no)
CA (1) CA2185129A1 (no)
FI (1) FI963638A (no)
NO (1) NO963848L (no)
WO (1) WO1995025124A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358385C (en) 1998-12-31 2013-08-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
EP1411770A4 (en) 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
DE60234843D1 (de) * 2001-09-06 2010-02-04 Centre Nat Rech Scient Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
CN101588813A (zh) * 2005-04-12 2009-11-25 杜克大学 诱导人类免疫缺陷病毒的中和抗体的方法
TW200726479A (en) 2005-04-12 2007-07-16 Univ Duke Method of inducing neutralizing antibodies to human immunodeficiency virus
EP2139516A4 (en) 2007-04-13 2011-06-29 Univ Duke METHOD FOR INDUCING NEUTRALIZING ANTIBODIES AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS
AU2010232915A1 (en) 2009-04-03 2011-10-20 Duke University Formulation for inducing broadly reactive neutralizing anti-HIV antibodies
US10076567B2 (en) 2013-09-27 2018-09-18 Duke University MPER-liposome conjugates and uses thereof
US10213482B2 (en) 2014-12-12 2019-02-26 Immupharma France Sa Methods of treating chronic inflammatory diseases

Also Published As

Publication number Publication date
FI963638A0 (fi) 1996-09-13
WO1995025124A1 (en) 1995-09-21
FI963638A (fi) 1996-11-13
AU2120595A (en) 1995-10-03
EP0750636A1 (en) 1997-01-02
JPH10504798A (ja) 1998-05-12
NO963848D0 (no) 1996-09-13
AU694204B2 (en) 1998-07-16
NO963848L (no) 1996-11-14

Similar Documents

Publication Publication Date Title
US8110203B2 (en) Adjuvant comprising non-toxic cross-linked muramyl dipeptide (MDP) microparticles derived from Propionibacterium acnes
Matthews et al. Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein.
US6265539B1 (en) Prophylaxis and therapy of acquired immunodeficiency syndrome
US9266928B2 (en) Deletion of the beta 20-21 loop in HIV GP120 exposes the CD4 binding site for improved antibody binding and antibody induction
US5603933A (en) CD4 peptides for binding to viral envelope proteins
GB2196634A (en) Monoclonal antibodies to HIV and related peptides
US5336758A (en) Peptides stimulating cytotoxic T cells immune to HIV RT
US6042831A (en) Human immunodeficiency virus type 1 (HIV-1) GP160 epitopes that are immunologically homologous to epitopes located in the class I major histocompatibility complex (MHC) heavy chain α-1 domain
CA2185129A1 (en) Methods to diagnose and treat hiv-1 infection
Liao et al. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains
AU694204C (en) Methods to diagnose and treat HIV-1 infection
WO1989010416A1 (en) PROTECTIVE PEPTIDES DERIVED FROM HUMAN IMMUNODEFICIENCY VIRUS-1 gp160
EP0910405B1 (en) Vaccine containing caprine arthritis-encephalitis virus and use for immunoprotection against hiv-1 infection
AU2006200454B2 (en) Compositions and methods for treating viral infections
US6290963B1 (en) Anti-HIV compositions containing native and recombinant peptides
CA2249736C (en) Caprine arthritis-encephalitis virus provides immunoprotection against hiv-1 infection
AU2004208648A1 (en) Compositions and methods for treating infections
AU4087693A (en) HIV protein epitopes immunologically homologous to HLA
AU2004201321A1 (en) Compositions and methods for treating viral infections
AU2006200455A1 (en) Compositions and methods for treating viral infections

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead